Free Trial

Terns Pharmaceuticals (TERN) News Today

Terns Pharmaceuticals logo
$3.30 -0.20 (-5.71%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$3.40 +0.11 (+3.18%)
As of 05/5/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Terns Pharmaceuticals, Inc. stock logo
JPMorgan Chase & Co. Reduces Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
JPMorgan Chase & Co. cut its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 70.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 51,830 shares of the company's stock after selling 123,506 shares during the qu
Terns Pharmaceuticals, Inc. stock logo
Acorn Capital Advisors LLC Invests $10.92 Million in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Acorn Capital Advisors LLC bought a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 1,971,264 shares of the company's stock, valued at approximately $10,921,000. Terns Pharmaceut
Terns Pharmaceuticals, Inc. stock logo
Boxer Capital Management LLC Takes $4.17 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Boxer Capital Management LLC acquired a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 752,000 shares of the company's
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Acquired by Schonfeld Strategic Advisors LLC
Schonfeld Strategic Advisors LLC grew its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 44.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,751,506 shares
Terns Pharmaceuticals, Inc. stock logo
Barclays PLC Purchases 575,069 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Barclays PLC grew its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 444.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 704,371 shares of the company's stock after purchasing an additional 575,069 shares duri
Terns Pharmaceuticals, Inc. stock logo
Marshall Wace LLP Grows Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Marshall Wace LLP boosted its stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 666.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 803,336 shares of the company's stock after buyi
Terns Pharmaceuticals, Inc. stock logo
Geode Capital Management LLC Has $8.40 Million Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Geode Capital Management LLC boosted its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 25.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,516,478 shares of the company's stock afte
Terns Pharmaceuticals, Inc. stock logo
Renaissance Technologies LLC Grows Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Renaissance Technologies LLC grew its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 30.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 623,134 shares of the company's stock a
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals (NASDAQ:TERN) Given Market Outperform Rating at JMP Securities
JMP Securities restated a "market outperform" rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a report on Monday.
Does Terns Pharmaceuticals Have A Long Cash Runway?
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Altium Capital Management LLC
Altium Capital Management LLC grew its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 43.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 475,000 shares of the company's stock after purchas
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock Position Raised by LPL Financial LLC
LPL Financial LLC raised its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 397.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 252,325 shares o
Terns Pharmaceuticals, Inc. stock logo
Russell Investments Group Ltd. Decreases Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Russell Investments Group Ltd. decreased its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 15.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 628,395 shares of
Terns Pharmaceuticals, Inc. stock logo
Alliancebernstein L.P. Has $2.01 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Alliancebernstein L.P. lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 48.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 362,359 shares of the company's stoc
Terns Pharmaceuticals, Inc. stock logo
Vanguard Group Inc. Has $21.44 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Vanguard Group Inc. lifted its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 15.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,869,582 shares of the comp
Terns Pharmaceuticals, Inc. stock logo
ExodusPoint Capital Management LP Lowers Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
ExodusPoint Capital Management LP lowered its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 99.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,816
Terns Pharmaceuticals, Inc. stock logo
Norges Bank Acquires New Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Norges Bank purchased a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 849,389 shares of the company's stock, valued at approximately $4,706,000
Terns Pharmaceuticals, Inc. stock logo
Polymer Capital Management HK LTD Increases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Polymer Capital Management HK LTD increased its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 637.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 177,000 shares of the compan
Terns Pharmaceuticals management to meet with Oppenheimer
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a
Oppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals, Inc. stock logo
William Blair Reaffirms Market Perform Rating for Terns Pharmaceuticals (NASDAQ:TERN)
William Blair reiterated a "market perform" rating on shares of Terns Pharmaceuticals in a report on Friday.
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06.
Terns Pharmaceuticals, Inc. stock logo
Candriam S.C.A. Buys New Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Candriam S.C.A. bought a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,153,969 shares of the company's stock, valued at approximately $11
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on Thursday
Terns Pharmaceuticals (NASDAQ:TERN) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.
Terns Pharmaceuticals, Inc. stock logo
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by Analysts
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The
Terns Pharmaceuticals, Inc. stock logo
William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)
William Blair assumed coverage on shares of Terns Pharmaceuticals in a report on Friday. They set a "market perform" rating on the stock.
Terns Pharmaceuticals sees cash runway into 2028
Mizuho Securities Remains a Buy on Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals appoints Andrew Gengos as CFO
Get Terns Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.

TERN Media Mentions By Week

TERN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TERN
News Sentiment

1.03

0.72

Average
Medical
News Sentiment

TERN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TERN Articles
This Week

7

3

TERN Articles
Average Week

Get Terns Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TERN) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners